<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01733589</url>
  </required_header>
  <id_info>
    <org_study_id>[2012]-10-24</org_study_id>
    <nct_id>NCT01733589</nct_id>
  </id_info>
  <brief_title>Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC</brief_title>
  <official_title>Multicenter Phase I/II Clinical Trial of Recombinant Human Endostatin Continued Pumping Into Vein Combining With Concurrent Chemo-Radiotherapy in the Patients With Unresectable Stage III Non-small-Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Cancer Hospital and Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangsu Cancer Institute &amp; Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First People's Hospital of Lianyungang</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Resistance of hypoxic tumor cells to radiation is a significant reason of failure in the&#xD;
      local control of tumors, especially the squamous cell carcinomas. Preclinical models have&#xD;
      shown that Endostar may transiently &quot;normalize&quot; the tumor vasculature to make it more&#xD;
      efficient for oxygen delivery, thereby providing a window of opportunity for enhanced&#xD;
      sensitivity to radiation treatment. This study is to evaluate the safety, toxicity, and&#xD;
      efficacy of the addition of Endostar Continued Pumping into Vein to the standard CCRT regimen&#xD;
      in patients with unresectable stage III NSCLC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary&#xD;
&#xD;
      Evaluate the efficacy and safety of Endostar combined with concurrent chemo-radiotherapy&#xD;
      (CCRT) in patients with unresectable stage III non-small-cell lung cancer (NSCLC).&#xD;
&#xD;
      Secondary&#xD;
&#xD;
      Measure changes in VEGF and other angiogenic cytokines and antiangiogenic factors in plasma&#xD;
      samples from these patients.&#xD;
&#xD;
      Evaluate the application of CT perfusion imaging to determine changes in tumor vascular&#xD;
      mophology and function during treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2012</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>2-year</time_frame>
    <description>from beginning treatment to progressive disease or the last follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>1 month</time_frame>
    <description>complete response(CR); partial response(PR); stable disease(SD); progressive disease(PD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>from date of beginning treatment until date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment related toxicities</measure>
    <time_frame>3 months</time_frame>
    <description>radiation-induced esophagitis; radiation-induced pneumonia</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Stage III Non-small-Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Recombinant Human Endostatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients received recombinant human endostatin(7.5mg/m2/24h) Continued Pumping Into Vein through 5 days at week 1, 3, 5, and 7. During week 2 through 8, patients received etoposide 50mg/m2 days 1-5 and cisplatin 50mg/m2 on day 1,8, every 4 weeks for two cycles with concurrent thoracic radiation at 60~66Gy in 30~33 fractions for 6~7 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant human endostatin</intervention_name>
    <description>Recombinant human endostatin(7.5mg/m2/24h) Continued Pumping Into Vein through 5 days at week 1, 3, 5, and 7,combined with concurrent chemo-radiotherapy.</description>
    <arm_group_label>Recombinant Human Endostatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide (50mg/m2) IV (in the vein) on day 1 to day 5 of a 28-day cycle for 2 cycles</intervention_name>
    <arm_group_label>Recombinant Human Endostatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatinum (50mg/m2) IV (in the vein) on day 1 and day 8 of a 28-day cycle for 2 cycles</intervention_name>
    <arm_group_label>Recombinant Human Endostatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>Recombinant Human Endostatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CT perfusion imaging</intervention_name>
    <arm_group_label>Recombinant Human Endostatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  untreated histologic or cytologic of NSCLC verified&#xD;
&#xD;
          -  inoperable stage IIIA or IIIB NSCLC&#xD;
&#xD;
          -  measurable disease by RECIST&#xD;
&#xD;
          -  18~70 years of age&#xD;
&#xD;
          -  an ECOG PS of 0 to 1&#xD;
&#xD;
          -  absolute neutrophil count (ANC) of ≥1500/μL, hemoglobin ≥10gm/dL, platelet ≥100,000/μL&#xD;
&#xD;
          -  serum creatinine ≤1.25 times of upper limit of normal (ULN), calculated creatinine&#xD;
             clearance (CrCl) of ≥60ml/min&#xD;
&#xD;
          -  bilirubin 1.5×ULN, AST and ALT less than 2.5×ULN, alkaline phosphatase less than 5×ULN&#xD;
&#xD;
          -  forced vital capacity in 1 second (FEV1) higher than 0.8 L&#xD;
&#xD;
          -  CB6 is normal&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  a history of other malignant diseases&#xD;
&#xD;
          -  any contraindications for chemoradiotherapy&#xD;
&#xD;
          -  distant metastasis&#xD;
&#xD;
          -  malignant pleural and/or pericardial effusion&#xD;
&#xD;
          -  pregnant or nursing&#xD;
&#xD;
          -  preexisting bleeding diatheses or coagulopathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming Chen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>November 2, 2012</study_first_submitted>
  <study_first_submitted_qc>November 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2012</study_first_posted>
  <last_update_submitted>July 11, 2017</last_update_submitted>
  <last_update_submitted_qc>July 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recombinant human endostatin</keyword>
  <keyword>Non-small-Cell Lung Cancer</keyword>
  <keyword>chemoradiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Endostatins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

